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Abstract
Objective
Expression of pro-inflammatory cytokines is influenced by single nucleotide polymorphisms
(SNPs) in the promoter regions of the pro-inflammatory cytokine genes, and cytokines are
associated with the occurrence of post-chemotherapy cognitive impairment. Hence, the
aim of this study was to evaluate the associations between two common pro-inflammatory
cytokine gene polymorphisms namely, IL6-174 (rs1800795 G>C) and TNF-308 (rs1800629
G>A), and chemotherapy-associated cognitive impairment (CACI) among Asian early-
stage breast cancer patients. In addition, the differential effect of these SNPs on plasma IL-
6 and TNF-α levels, and the associations of plasma IL-6 and TNF-α levels with CACI were
also assessed.
Methods
Asian early-stage breast cancer patients (Stage I to III) receiving chemotherapy were pro-
spectively recruited from two cancer centers in Singapore. Patients’ cognitive function was
longitudinally assessed using the validated FACT-Cog (ver. 3) and an objective computer-
ized battery, Headminder™ at three-time points. Plasma IL-6 and TNF-α levels were ana-
lyzed using the multiplex immunoassay, and genotyping was performed using Sanger
sequencing. Regression analyses and generalized estimating equation were utilized for
statistical analysis.
Results
A total of 125 patients were included (mean age: 50.3; Chinese: 80.8%; post-menopausal:
48.0%; 68.0% received anthracycline-based chemotherapy). 36.8% patients experienced
self-perceived cognitive impairment, detected in memory (32.8%) and attention (34.2%)
domains. Patients with higher levels of anxiety (p<0.001) and insomnia (p = 0.003) also
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reported more self-perceived cognitive impairment. Higher plasma concentrations of IL-6
were associated with greater severity of self-perceived cognitive impairment (p = 0.001).
Polymorphisms of cytokine genes were not associated with expression of plasma cytokines.
Conclusion
Present findings further contribute to the growing evidence that supports the role of the pro-
inflammatory cytokine IL-6 in the occurrence of cognitive impairment post-chemotherapy.
However, genetic polymorphism of these cytokines did not play a major role to the cytokine
fluctuations as well as cognitive impairment in this cohort. With an increasing evidence to
support the cytokine hypothesis, future studies should investigate the role of anti-inflamma-
tory agents in mitigating the cognitive impairment associated with chemotherapy.
Introduction
On the physiological level, inflammatory cytokines play important roles in the central nervous
system (CNS) to modulate neuronal and glial cell functioning and neuronal repair [1–3]. How-
ever, the use of anticancer treatment coupled with patients’ psychological distress could trigger
the inflammation cascade, which could lead to cytokine dysregulation. In patients with cancer,
such inflammation cascade is speculated to increase one’s risk for subtle changes in cognition.
This phenomenon is also known as cancer-associated cognitive impairment (CACI) or ‘che-
mobrain’ in the literature.
Evidence suggests that expression of pro-inflammatory cytokines is influenced by single
nucleotide polymorphisms (SNPs) in the promoter regions of the pro-inflammatory cytokine
genes. For example, the TNF-308G>A (rs1800629) polymorphism has been associated with
high transcriptional activity, which increases the secretion levels of TNF-α, whereas the IL6-
174G>C (rs1800795) polymorphism has been reported to influence the expression of IL-6,
with carriers of the G allele being associated with higher plasma concentrations of IL-6 [4–6].
Few studies have been performed to evaluate the association between these SNPs and cognitive
impairment in cancer patients. One study reported that carriers of the G allele of IL6-174G>C
(rs1800795) were associated with poorer attention [7]. Another study suggested that carriers of
high-expression alleles of IL6-174 and TNF-308were associated with poorer memory in breast
cancer patients [8]. Taken together, current findings suggest that host genetic factors could
contribute to differential expression of the pro-inflammatory cytokines, which in turn translate
to varying degrees of susceptibility to CACI among patients.
Singapore is a multiracial country with a majority population of Chinese,Malay and Indian,
with English and Chinese being the most commonly spoken languages. As genetic polymor-
phisms are known to be demographic specific, it would be of great interest to determine the
effect of these SNPs on cognitive function in the Singapore population, where information of
such associations is sparse. (Fig 1) To the best of our knowledge, the association between these
polymorphisms and cognitive function among Singapore multi-ethnic population are
unknown.Hence, the aim of this study was to evaluate the associations between pro-inflamma-
tory cytokine gene polymorphisms namely, IL6-174 (rs1800795 G>C) and TNF-308
(rs1800629 G>A), and CACI among early-stage breast cancer patients in Singapore. In addi-
tion, the differential effect of these SNPs on plasma IL-6 and TNF-α levels, and the associations
of plasma IL-6 and TNF- α levels with CACI were also assessed.
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Materials and Methods
Study design
Patients were recruited at the National Cancer Centre of Singapore (NCCS) and KKWomen’s
and Children’s Hospital (KKH) in Singapore. This was a prospective, longitudinal, cohort
study approved by the SingHealth Centralized Institutional ReviewBoard (IRB), and written
informed consent was obtained from all participants.
Inclusion and exclusion criteria
Eligible patients fulfilled the following criteria: (i) at least 21 years of age diagnosed early-stage
breast cancer (stages I to III) by a medical oncologist, (ii) scheduled to receive chemotherapy,
either doxorubicin with cyclophosphamide (AC) or docetaxel with cyclophosphamide (TC),
Fig 1. A conceptual framework including determinants that might affect cognitive impairment in chemotherapy-treated breast cancer
patients. This study was performed to evaluate the downstream effects of TNF-308 and IL6-174 polymorphisms on the circulating TNF-α and IL-6
levels, and the occurrence of chemotherapy-associated cognitive impairment.
doi:10.1371/journal.pone.0164204.g001
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(iii) had no prior chemotherapy and/or radiotherapy, (iv) had Eastern CooperativeOncology
Group (ECOG) score of 0 or 1, and (v) were fluent with either English or Chinese.
Patients were excluded if they were: (i) documentedwith brain metastasis and/or any neuro-
psychiatric disorders that might result in poor cognitive abilities, (ii) acute illness (e.g. fever),
and (iii) physically or mentally incapable of giving written informed consent.
Brain imaging was performed for patients diagnosedwith stage III breast cancer, and all
study participants were confirmed by their treating medical oncologists for the absence of
brain metastasis and leptomeningeal disease.
Study procedures
Data was collected at 3 independent time points: baseline (T1; before the initiation of chemo-
therapy), during chemotherapy (T2; 6 weeks after the initiation of treatment), and post-chemo-
therapy (T3; 12 weeks after the initiation of treatment).
Before the initiation of chemotherapy, clinical characteristics of participants (age, height/
weight, race, marital status, education level, and occupation),medical information (cancer
diagnosis, cancer stage, comorbidities, ECOG) and medical history (chemotherapy regimen,
dose intensity, duration) were obtained from the electronicmedical records and through inter-
views of participants. At each time point of data collection, patients completed two types of
neuropsychological assessment tools using Headminder™ (provided by Headminder, Inc. to
assess objective cognitive function) and FACT-Cog (to assess self-perceived cognitive func-
tion). Furthermore, health-related quality of life (HRQoL), anxiety, and fatigue were also
assessed using patient reported outcome questionnaires [9–12]. All cognitive assessments were
available in English or Chinese, and were administered by trained bilingual interviewers. For
each time point, all assessments took roughly 40 minutes for participants to complete.
Cytokine analysis and Genotyping
At each time point, a 10-ml bloodwas collected from the volunteers prior to the receiving of
chemotherapy, and stored in an ethylene diamine tetraacetic acid (EDTA) tube. Within 30 to
40 minutes of collection, the blood sample was centrifuged at 1,140 g (2,500 rpm) for 30 min.
The plasma and buffy coat were subsequently stored aseptically at −80°C until analysis.
Prior to cytokine analysis, plasma samples were thawed and centrifuged at 10,000g for 10
min at 40°C. The plasma supernatant was used for detection of TNF-α and IL-6 by using the
Bio-Plex proTM Human cytokine 8-plex assay kit (Bio-rad). Samples were analyzed in tripli-
cates and the assay was performed according to the manufacturer’s instructions. The plate was
assayed with the Bio-plex 200 multiplex reader and cytokine concentrations were calculated
using the Bio-Plex Manager software v6.0 (Bio-rad).
Genomic DNA was isolated from the buffy coat via the QIAamp DNA BloodMini Kit (Qia-
gen). The section containing the polymorphisms of IL6-174 (rs1800795 G>C) and TNF-308
(rs1800629 G>A) was amplified by polymerase chain reaction (PCR) using specific and opti-
mized primers. Primers utilized for PCR amplification were as follows: 5’-ATGCCAAAGTGC
TGAGTCACTA-3’ (forward), 5’-TCGAGGGCAGAATGAGCCTC-3’ (reverse) for IL6-174
(rs1800795 G>C), and 5’-TCCTGCATCCTGTCTGGAA-3’ (forward), 5’-CAGCGGAAA
ACTTCCTTGGT-3’ (reverse) for TNF-308 (rs1800629 G>A). Genotyping was conducted by
AITbiotech and they were blinded to all clinical outcomes.
Statistical Analysis
All statistical analyses were conducted using Stata Version 14 (StataCorp, 2015).
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A simple Friedman test was utilized to evaluate the change in plasma cytokine levels over
the three time points. Mann–Whitney U-test was used to compare the plasma cytokine levels
between the genotype groups for IL6-174 and TNF-308 at each time point.
The association of cognitive impairment, as depicted by the global FACT-Cog score (self-
perceived cognitive impairment) and the four Headminder™ cognitive domains (objective),
with plasma cytokines concentrations during chemotherapy, was evaluated using the general-
ized estimating equation (GEE) model. For Headminder™, the reliable change index (RCI) was
acquired considering the repeated normative mean and standard error of the difference for
adjusting the practice effect. Participants were defined as having cognitive impairment in each
individual computerized cognitive domain if the RCI was lower than -1.5. A best-fittedmodel
was subsequently created to delineate the association between cognitive impairment and
plasma cytokines concentrations after adjusting for documented clinically relevant variables.
Clinical confounders that might influence cognitive functionwere also included a priori into
the GEEmodel as fixed effects; these variables were age, anxiety, fatigue, bodymass index
(BMI), chemotherapy regimens group (AC versus TC), insomnia, menopausal status, stage of
cancer and years of education. Selection of the appropriate correlation structures in the GEE
model was conducted using the quasi-likelihoodunder the independencemodel criterion, the
structure exhibiting the smallest criterion was considered to be the most desirable.
The genetic association between IL6-174 (rs1800795 G>C) and TNF-308 (rs1800629 G>A)
polymorphisms with CACI was assessed using logistic regression. For FACT-Cog, the minimal
clinically important difference (MCID) is defined based on the reduction of10.6 points in
the FACT-Cog total score during T2 or T3 compared with T1. Similar to the GEEmodel, vari-
ables that might influence cognitive impairment were also inserted a priori into the logistic
regression model. Results were reported as odds ratios (ORs) and 95% confidence intervals
(CIs). All statistical tests were two-sided, and p<0.025 was considered statistically significant.
Results
Patient Demographics
Patients’ demographics are summarized in Table 1. Their mean age ± SD was 50.3 ± 8.8 years.
They were predominantly Chinese (80.8%), and majority (84.0%) received at least high school
education and above. Most participants (93.6%) were ambulatory without restrictions on activ-
ities, as reflected by an Eastern CooperativeOncologyGroup performance status of 0 (fully
ambulatory) at baseline assessment. Eighty-five patients (68.0%) received an anthracycline-
based chemotherapy regimen.
Occurrence of Objective and Self-Perceived Cognitive Impairment
Based on theMCID of FACT-Cog, 36.8% (n = 46) patients experienced self-perceived cognitive
impairment. With regards to the Headminder™ cognitive domains, the most commonly
affected domains were memory (32.8%, n = 40) and attention (34.2%, n = 39).
Genotype and Allele Frequencies
All 125 patients were genotyped for the IL6-174 (rs1800795 G>C) and TNF-308 (rs1800629
G>A) polymorphisms (Table 2). Genotype frequencies of IL6-174 and TNF-308 did not devi-
ate from the Hardy–Weinberg equilibrium, respectively (p = 0.80, p = 0.97). The GG genotype
of IL6-174 and TNF-308 constituted 97.6% and 83.2% of the observed genotypes, respectively.
The C allele of IL6-174 and the A allele of TNF-308 accounted for approximately 1.2% and
8.8% of the observed alleles, respectively.
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Trajectory of Plasma IL-6 and TNF- α Levels
Across the three-time points, there were significant changes in the plasma IL-6 and TNF-α
concentrations (p<0.001), with the highest plasma concentrations occurring at the end of che-
motherapy (Table 3). Post-hoc analysis showed that the concentration of IL-6 was significantly
higher at end of chemotherapy when compared to T2 and T1 (p<0.001). However, post-hoc
analysis of plasma TNF-α concentration across time did not achieve statistical significance at
any specific time point.
A subgroup analysis was conducted to evaluate the changes in plasma IL-6 and TNF-α con-
centrations after stratifying for the IL6-174 (rs1800795 G>C) and TNF-308 (rs1800629 G>A)
genotypes (Table 4). It was observed that there was a significant increase in plasma IL-6 con-
centration among patients who were carriers of the GG genotype of IL6-174, and pair-wise
comparisons showed a higher IL-6 concentration at the end of chemotherapy than T2 and T1.
Table 1. Demographics and clinical information of the patients (N = 125).
n (%)
Age, y, mean ± SD 50.26 ± 8.82
Ethnicity Chinese 101 (80.80)
Malay 13 (10.40)
Indian 7 (5.60)
Othersa 4 (3.20)
Education Primary school 20 (16.00)
Secondary school 58 (46.40)
Pre-university 25 (20.00)
Graduate/postgraduate 22 (17.60)
Marital status Single 29 (23.20)
Married 85 (68.00)
Divorced 9 (7.20)
Widowed 2 (1.60)
Working status Currently working 69 (55.20)
Currently not working 56 (44.80)
Cancer stage 1 22 (17.60)
2 66 (52.80)
3 37 (29.60)
ECOG performance status 0 117 (93.60)
1 8 (6.40)
Menopausal status Pre-menopausal 65 (52.00)
Post-menopausal 60 (48.00)
Chemotherapy regimen Doxorubicin-containing 85 (68.00)
Docetaxel-containing 40 (32.00)
Behavior symptoms, mean ± SD
Baseline fatigue (BFI total score)b 1.54 ± 1.76
Baseline anxiety (BAI total score)c 6.94 ± 6.27
Baseline insomnia scored 23.03 ± 27.70
Abbreviation: ECOG, Ea Eastern Cooperative Oncology Group.
aOthers includes 1 Burmese and 3 Filipinos.
bBFI total score is 10 points.
cBAI total score is 63 points.
dInsomina subscale total score is 100 points.
doi:10.1371/journal.pone.0164204.t001
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After stratifying for the TNF-308 genotype, significant increase of plasma TNF-α concentration
from T1 to T3 was observed in both GG and GA genotype groups, however, post-hoc analysis
did not identify any significant differences in TNF-α between any two time points.
Genetic Association of IL6-174 and TNF-308 Polymorphisms with CACI
For both self-perceived and objective cognitive impairment, no associations were established
with IL6-174 and TNF-308 polymorphisms (S1 and S2 Tables).
Association of Plasma IL-6 and TNF- α Levels with CACI
Higher plasma IL-6 concentrations were strongly related to severity of self-perceived cognitive
impairment (p = 0.001) (Table 5). Both anxiety and insomnia were also strong determinants of
self-perceived cognitive impairment; patients with higher levels of anxiety and insomnia
reportedmore cognitive impairment (p<0.001, p = 0.003), respectively.
No associations were established between plasma IL-6 levels and the cognitive domains of
Headminder™. However, stage of breast cancer was associated with objective impairment in the
domains of attention and processing speed (p = 0.049 and 0.041, respectively). Patients who
were older, with higher BMI and insomnia scores had significant association with poorer atten-
tion (p = 0.032, 0.008, and 0.003, respectively). Both fatigue and insomnia were also strong
determinants of poorermemory (p = 0.004 and 0.035, respectively).
In contrast to IL-6, plasma TNF-α levels were not associated with both self-perceived and
objective cognitive impairment.
Table 2. Genotype and allele frequencies of the IL6-174 (rs1800795) and TNF-308 (rs1800629), (N = 125)
Genetic Variant Genotype Frequency, n (%) Allele Frequency n (%)
IL6–174 G>C (rs1800795) GG GC CC G C
Chinese 101 (82.8) 0 (0) 0 (0) 202 (81.8) 0 (0)
Malay 12 (9.8) 1 (33.3) 0 (0) 25 (10.1) 1 (33.3)
Indian 5 (4.1) 2 (66.7) 0 (0) 12 (4.9) 2 (66.7)
Others* 4 (4.3) 0 (0) 0 (0) 8 (3.2) 0 (0)
Total 122 (97.6) 3 (2.4) 0 (0) 247 (98.8) 3 (1.2)
TNF-308 G>A (rs1800629) GG GA AA G A
Chinese 83 (79.8) 17 (85) 1 (100) 183 (80.3) 19 (86.4)
Malay 12 (11.5) 1 (5) 0 (0) 25 (10.9) 1 (4.5)
Indian 5 (4.8) 2 (10) 0 (0) 12 (5.3) 2 (9.1)
Others* 4 (3.8) 0 (0) 0 (0) 8 (3.5) 0 (0)
Total 104 (83.2) 20 (16) 1 (0.8) 228 (91.2) 22 (8.8)
* Others includes 1 Burmese and 3 Filipinos.
doi:10.1371/journal.pone.0164204.t002
Table 3. Plasma IL-6 and TNF-α concentrations across the three time-points, (N = 125).
Cytokines Cytokine concentrations (pg/mL) Median (interquartile range) p-value Post hoc (p-value)*
T1 T2 T3 T2 vs. T1 T3 vs. T2 T3 vs. T1
IL-6 1.08 (0.00–2.84) 0.97 (0.00–3.31) 2.28* (0.00–5.43) < 0.001 0.39 < 0.001 < 0.001
TNF-α 1.26 (0.00–3.66) 1.49 (0.00–3.54) 2.08 (0.56–3.66) < 0.001 0.29 0.02 0.33
*p-value cut-off for post-hoc analysis: 0.0167.
doi:10.1371/journal.pone.0164204.t003
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Discussion
This study evaluated the genetic associations of IL6-174 (rs1800795 G>C) and TNF-308
(rs1800629 G>A) with CACI and cytokine fluctuations within an Asian early-stage breast can-
cer population. Both IL6-174 (rs1800795 G>C) and TNF-308 (rs1800629 G>A) polymor-
phisms are highly monomorphic in the Singaporean population. In addition, plasma IL-6 and
TNF-α concentrations did not differ significantly among the various genotypes, suggesting
that both SNPs are not the main factors that drive the over-expression of plasma IL-6 and
TNF-α concentrations after initiation of chemotherapy. Although we were unable to establish
the genetic associations with cognitive impairment, we have observed that patients manifesting
higher levels of IL-6 were associated with greater severity of self-perceived cognitive
impairment.
Previous studies have evaluated the downstream effects of TNF-308G>A (rs1800629) and
IL6-174G>C (rs1800795) cytokine gene polymorphisms on the expression of the cytokine lev-
els, as well as the onset of various human illnesses. One study suggested that asthmatic patients
Table 4. Plasma IL-6 and TNF-α concentrations across the three time-points, after stratifying for the IL6-174 and TNF-308 genotypes (N = 125)
Cytokines Cytokine concentrations (pg/mL) Median (interquartile range) p-value Post hoc (p-value)*
IL6-174 Genotype T1 T2 T3 T2 vs. T1 T3 vs. T2 T3 vs. T1
GG (n = 122) 1.08 (0.00–2.84) 0.93 (0.00–3.29) 2.28 (0.00–5.43) <0.001 0.47 0.001 <0.001
GC (n = 3) 0.50 (0.25–3.06) 1.09 (0.83–3.18) 2.49 (1.75–5.30) 0.05 0.29 0.11 0.11
CC (n = 0) - - - NA NA NA NA
TNF-308 Genotype T1 T2 T3 T2 vs. T1 T3 vs. T2 T3 vs. T1
GG (n = 104) 1.23 (0.00–3.52) 1.39 (0.00–3.65) 2.05 (0.57–3.66) <0.001 0.18 0.32 0.02
GA (n = 20) 0.98 (0.00–4.50) 1.70 (0.00–2.63) 2.65 (0.22–3.22) <0.001 0.44 0.57 0.85
AA (n = 1) 8.81 58.03 44.62 NA NA NA NA
*p-value cut-off for post-hoc analysis: 0.0167. NA = Not applicable
doi:10.1371/journal.pone.0164204.t004
Table 5. Association of IL-6 concentrations with severity of self-perceived cognitive impairment (FACT-Cog) and the cognitive domains of
Headminder™.
FACT-Cog Headminder™
Global score (n = 125) Attention (n = 114) Memory (n = 122) Processing speed
(n = 115)
Response speed
(n = 122)
Coefficient
(SE)
p-value Coefficient
(SE)
p-
value
Coefficient
(SE)
p-
value
Coefficient
(SE)
p-
value
Coefficient
(SE)
p-
value
Constant 123.696
(11.080)
<0.001 -5.483 (1.916) 0.004 -1.518 (1.900) 0.425 -1.190 (3.624) 0.600 -1.850 (2.624) 0.481
IL-6 -0.036 (0.011) 0.001 0.004 (0.003) 0.177 -0.002 (0.004) 0.638 -0.015 (0.026) 0.560 0.002 (0.002) 0.298
Age 0.285 (0.165) 0.085 0.060 (0.028) 0.032 0.005 (0.028) 0.853 0.099 (0.056) 0.075 -0.028 (0.036) 0.435
Anxiety -1.079 (0.131) <0.001 -0.016 (0.028) 0.566 -0.037 (0.032) 0.253 -0.139 (0.084) 0.098 0.024 (0.033) 0.461
Fatigue -0.381 (0.485) 0.423 -0.029 (0.101) 0.775 0.296 (0.103) 0.004 0.336 (0.213) 0.114 0.182 (0.118) 0.123
Body Mass Index -0.102 (0.238) 0.670 0.104 (0.039) 0.008 0.018 (0.038) 0.640 0.011 (0.068) 0.868 0.182 (0.053) 0.883
Chemotherapy
group
0.122 (2.563) 0.962 -0.809 (0.460) 0.079 0.039 (0.434) 0.928 -1.907 (0.990) 0.054 0.018 (0.569) 0.975
Insomnia -0.090 (0.030) 0.003 0.019 (0.007) 0.003 -0.016 (0.007) 0.035 -0.014 (0.015) 0.350 -0.005 (0.008) 0.525
Menopausal status 0.340 (2.871) 0.906 -0.897 (0.501) 0.074 0.013 (0.488) 0.979 -0.433 (0.905) 0.632 0.067 (0.629) 0.916
Years of education 0.387 (0.312) 0.215 0.021 (0.050) 0.670 -0.056 (0.052) 0.280 -0.092 (0.097) 0.344 -0.006 (0.070) 0.930
Breast Cancer
stage
0.573 (1.761) 0.745 -0.598 (0.304) 0.049 -0.177 (0.294) 0.548 -1.216 (0.596) 0.041 0.035 (0.377) 0.925
doi:10.1371/journal.pone.0164204.t005
The Downstream Effects of Genetic Polymorphism on Cytokine Plasma Levels, and Cognitive Impairment
PLOS ONE | DOI:10.1371/journal.pone.0164204 October 4, 2016 8 / 13
who were carriers of the A allele (AA and AG genotypes) of the TNF-308G>A (rs1800629)
genetic polymorphism had significantly higher serumTNF-α levels, which was also signifi-
cantly associated with metabolic syndrome [13]. Similar findings were also observed in other
inflammatory conditions including depression and inflammatory bowel disease [14, 15]. On
the contrary, current evidence to evaluate the impact of these polymorphisms on cognitive
function is limited. One recent cross-sectional study has evaluated the associations between the
two SNPs and memory complaint among breast cancer patients. It was found that the overall
genetic risk index was associated with memory complaint, however, an examination of the
individual contribution of each SNP did not identify any significant association with memory
complaint [16]. This is in consistent with the current findings where no associations were
established between the SNPs and cognitive impairment among chemotherapy receiving breast
cancer patients.
In this study, the absence of association between the TNF-308 (rs1800629 G>A) polymor-
phism and cognitive decline could be attributed to the low allele frequency of the TNF-308G/A
polymorphism in our study population, which comprises mainly of Chinese patients. The low fre-
quency of the risk allele was also reported in other genetic association studies that were conducted
in the Han Chinese populations [17, 18]. Nevertheless, it must be emphasized that the lack of
association betweenTNF-308G/A polymorphism and CACI impairment does not undermine the
role of this polymorphism in influencing the expression of TNF-α. In our analysis, we have also
observed that plasma TNF-α levels were much elevated (8.81 to 58.03 pg/ml) in one patient who
was a homozygous carrier for the risk allele. This finding is similar to another study where the AA
genotype frequencywas approximately 0.8% (n = 2), and it was observed that TNF-α levels were
highly elevated among patients whose genotype was homozygous recessive [19]. Similar to our
findings, they were also unable to establish an association between the TNF-308G/A polymor-
phism and disease status. Taken together, these findings suggest that TNF-308G/A polymorphism
is not the factor influencing circulating TNF-α levels in the majority of our local population, but
this could be different in populations with a higher prevalence of the risk allele.
In contrast to the TNF-308G/A polymorphism, the major allele of IL6-174G/C polymor-
phism is associatedwith higher levels of IL-6 [20, 21]. Hence, one would expect to observe higher
plasma IL-6 levels among patients who are carriers of the G allele, and the resultant increase in
IL-6 levels would be associatedwith cognitive impairment. Even though the current study did
observe an association betweenplasma IL-6 levels and self-perceived cognitive impairment, we
did not observe a dose response change of plasma IL-6 levels for each addition of the minor allele
due to the dominance of the GG genotype (98.8%) in the local population. Henceforth, the
absence of association between the IL6-174G/C polymorphism and cognitive impairment could
be attributed largely to the monomorphic nature of the SNP in the local population.
Conversely, dysregulation of cytokines could be attributed to a number of conditions, such
as the malignancy, the anticancer treatments, as well as the physical and psychological stressors
[22, 23]. In particular, cell death and injury that are caused by chemotherapeutic agents, cou-
pled with both intrinsic and extrinsic stressors, could lead to the peripheral activation of the
inflammatory response. IL-6 and TNF-α are primary pro-inflammatory cytokines that could
exhibit an acute phase response to tissue injury, infection, or inflammation [24]. The release of
peripheral pro-inflammatory cytokines could perturb cytokine levels in the central nervous
system, and leads to alterations in neuronal function. In the current study, plasma IL-6 levels
were associated with self-perceived cognitive impairment. This finding is consistent with prior
studies that have drawn an association between fluctuation in plasma IL-6 levels and self-per-
ceived cognitive disturbances [25–27]. Although TNF-α was also reported to be associated
with self-reportedmemory complaints at baseline and longitudinally among breast cancer
patients, the current study failed to establish an association between plasma TNF-α levels and
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cognitive impairment [28]. The inconsistency in results could be attributed to methodological
differences. In a cohort study conducted by Ganz et al, the authors evaluated soluble TNF-
receptor II levels at 3 months, 9 months and 15 months after completion of primary treatment,
whereas the current study measured plasma TNF-α levels during chemotherapy. It must be
emphasized that the biological activity of TNF-α could be limited by its relatively short half-
life. Soluble TNF-receptors, on the other hand, have been shown to function as a buffer system
to prolong the biological effects of TNF-α. As such, TNF-receptors could be more essential for
monitoring inflammatory responses associated with TNF-α.
In line with other studies, cytokine levels (IL-6) were strongly associated with self-perceived
cognitive impairment [29, 30]. Dysregulation of pro-inflammatory cytokines are often
observed in patients who are experiencing stress-induced symptoms. In our study, we have
also identified other stressors such as anxiety and insomnia that are contributing to self-per-
ceived cognitive impairment. Hence, besidesmeasuring how cognitive complaints could subtly
impact daily life, self-perceived cognitive impairment is also useful to reflect the degree of emo-
tional and physical symptoms that are experienced among patients [31]. On the other hand,
cytokine levels were not associated with impairment in any HeadminderTM domains, as objec-
tive neuropsychological testing merely captures the cognitive status of a patient at the point of
testing [29]. In summary, in epidemiological studies that aim to evaluate the role of pro-inflam-
matory cytokines on cognitive impairment, it would be prudent to include both subjective and
objectivemeasures of cognition as both measures possess different significance.
There are a number of limitations in this study. A number of genetic variations associated
with IL-6 and TNF-α were not evaluated in the current study. For example, the IL6-634 SNP
has been shown to be associated with higher circulating serum IL-6 levels [32]. It must be
emphasized that the two selected SNPs in this study were based on the functional consequences
such as fatigue, depression, and memory complaints that were previously established in the
breast cancer population [8]. Higher levels of these cytokines were also strongly associated with
cognitive impairment in chemotherapy-breast cancer patients [26, 27]. Hence, we selected
these two candidate SNPs in order to establish genuine epidemiological association in our own
population. Future studies should evaluate the impact of these other polymorphisms on circu-
lating IL-6 and TNF-α levels, and the resultant association with CACI. Recent studies have also
suggested that mitochondrial dysfunctions are correlated with oxidative stress and inflamma-
tion in cognitive disorders such as Alzheimer’s disease. [33–37] Future studies should also eval-
uate how mitochondrial dysfunctionsmay contribute to CACI in patients with cancer.
Conclusion
Present findings further contribute to the growing evidence that supports the role of the pro-
inflammatory cytokine IL-6 in the occurrence of cognitive impairment post-chemotherapy.
However, genetic polymorphism of these cytokines did not play a major role to the cytokine
fluctuations as well as cognitive impairment in this cohort. Currently, the lack of understand-
ing of the biologicalmechanisms underpinningCACI remains the major impediment to the
development of effectivemanagement strategies.With an increasing evidence to support the
cytokine hypothesis, future studies should investigate the role of anti-inflammatory agents in
mitigating the cognitive impairment associated with chemotherapy.
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